After 60-min HS, hearts were harvested and resuscitated ex vivo
by perfusion using the Langendorff apparatus for 60-min [Figure 1].
Given the advantage of observing the progression of a living specimen over a long period of time, in real-time, without damage to the tissue under investigation, in vivo applications are likely to continue growing in importance relative to traditional ex vivo
research, extending the boundaries of the technology.
The addition of this ex vivo
assay permits the rapid treatment and analysis of hair, confirming its utility in biomarker programs before commencing more costly clinical studies with patients.
The results after transplantations using ex vivo
evaluated lungs were at least as good as in the control group according to Dr.
According to CSL, the two technologies have multiple applications in ex vivo
stem cell gene therapy.
The elevations in dialysate DA concentrations seen here are strikingly similar to those seen in media DA concentrations after acute ex vivo
exposure of adult rat striatal tissue to Aroclor mixtures (Bemis and Seegal 1999; Chishti et al.
announced today that results from a preclinical study of GX15-070 in mantle cell lymphoma (MCL) cell lines and ex vivo
patient samples showed that GX15-070 and bortezomib (Velcade) exhibit synergistic activity, due to the ability of GX15-070 to potently antagonize the Bcl-2 family member, Mcl-1.
Calimmune Inc is a biotechnology company that is focused on the development of ex vivo
hematopoietic stem cell (HSC) gene therapy with R&D facilities in Pasadena, California and Sydney, Australia.
We propose adrenal slice culture as a simple ex vivo
test system with which to examine the adrenocorticolytic activity of xenobiotics in human and wild animal tissue.
from Tulane University (New Orleans, LA) and Tulane's Health Science Center describe the revolutionary advances achieved in identifying the optimal adult stem cell sources for generating tissue substitutes and refining the complex processes required to grow these cells ex vivo
and induce them to replicate and differentiate into specific tissue types.
In addition, GSK will co-develop with Fondazione Telethon and Fondazione San Raffaele, six further applications of ex vivo
stem cell therapy, using a new gene transfer technology developed by HSR-TIGET scientists, with the potential to treat a range of rare disorders.
The settlements allow Transkaryotic to practice its non-viral ex vivo
gene therapy under royalty-free licenses in the event that any broad claims to gene therapy survive the original interference or issue in any of the pending interferences.